Key aspects of the use of new-generation probiotic strains in 3P medicine: challenges and perspectives
DOI:
https://doi.org/10.32782/2786-7684/2024-1-5Keywords:
biological preparations, new generation probiotics, gut microbiome, pharma-biotics, personalized medicineAbstract
Today, the production of «new generation» pharmabiotics faced to new challenges due to the attempt to expand the use of new atypical probiotic strains. This review highlights the potential of using new generation probiotic strains (probiotics, metabiotics, NGPs) as active components of the latest probiotic drugs with proven clinical efficacy. Aim of study. To study the possibility of using atypical probiotic strains and to evaluate their potential for creating new generation pharmabiotics. Materials and methods. The work is based on the analysis and systematization of own experimental and theoretical scientific data. Results and discussion. The gut microbiota interacts with almost all organs, including the central nervous system, in the so-called «gut-brain» axis. The microbiome of healthy individuals can be a source of promising probiotic microbial strains for the development of pharma-biotics for the prevention and treatment of diseases of various etiologies. When creating probiotic preparations, it is necessary to pay attention to the safety of the strains, their ability to regulate the local and systemic immune response, antagonistic activity and the presence of separately defined adhesive properties. At the same time, they should not have any inhibitory effect on commensal microorganisms. Conclusions. Various types of biological preparations (pre-, pro-, syn-, metabiotics) are used to restore and correct the microbiota of the gastrointestinal tract. With the development of modern technologies, it became possible to use next-generation probiotics, which became a breakthrough in the production of new-generation biological preparations. However, their use has its own limiting factors, one of which is the insufficient number of clinical studies on effectiveness and detection of possible side effects.
References
The usage of probiotics in case of diseases of the gastrointestinal tract associated with other pathological processes: for and against. Бончужна, М. В., Мажак, К. Д., Мотика, О. І., Слесарчук, О. М., Топорович, О. І. Актуальні Проблеми Профілактичної Медицини, 25, 2024. 12–21. https://doi.org/10.32782/2786-9067-2023-25-2
Probiotics and pharmabiotics. Bioengineered Bugs / Hill, C. 1(2), 79–84. 2010 https://doi.org/10.4161/bbug.1.2.10796
The concept of probiotics, prebiotics, postbiotics, synbiotics, nutribiotics, and pharmabiotics. Chaudhari, A., & Dwivedi, M. K. Probiotics in the Prevention and Management of Human Diseases, 2022. 1–11. https://doi.org/10.1016/b978-0-12-823733-5.00013-1
Кишкова мікробіота та неалкогольна жирова хвороба печінки: нові аспекти та невирішені питання. / Черелюк, Н. І., & Курінна, О. Г. Медицина сьогодні і завтра, 82(1), 2020. 16–22. https://doi.org/10.35339/msz.2019.82.01.03
Microbiome in 3P Medicine Strategies. In N. Boyko O. Golubnitschaja (Eds.), Advances in Predictive, Preventive and Personalised Medicine. Springer International Publishing. 2023. https://doi.org/10.1007/978-3-031-19564-8
Gut microbiota-derived metabolites in obesity: a systematic review. Ejtahed H.-S., Angoorani P., Soroush, A.-R., Hasani-Ranjbar S., Siadat, S.-D., Larijani, B. Bioscience of Microbiota, Food and Health, 39(3), 2020. 65–76. https://doi.org/10.12938/bmfh.2019-026
Our Gut Microbiome: The Evolving Inner Self. Cell / Kundu, P., Blacher, E., Elinav, E., Pettersson, S. 2017, 171(7), 1481–1493. https://doi.org/10.1016/j.cell.2017.11.024
Pro- Pre- and Synbiotic Supplementation and Oxalate Homeostasis in 3 PM Context: Focus on Microbiota Oxalate-Degrading Activity. Advances in Predictive, Preventive and Personalised Medicine. Tolstanova, G., Akulenko, I., Serhiichuk, T., Dovbynchuk, T., Stepanova, N. 2023. 335–353. https://doi.org/10.1007/978-3-031-19564-8_12
Еffects of mono-, poly- and composite probiotics on the ulceration caused by restraint stress. / Virchenko, O. V., Falalyeyeva, T. M., Beregova, T. V., Spivak, M. Y., Lazarenko, L. M., Demchenko, O. M. Fiziolohichnyĭ Zhurnal, 61(1), 2015. 35–41. https://doi.org/10.15407/fz61.01.035
How Probiotics Affect the Microbiota / Wieërs, G., Belkhir, L., Enaud, R., Leclercq, S., Philippart de Foy, J.-M., Dequenne, I., de Timary, P., Cani, P. D. 2020. Frontiers in Cellular and Infection Microbiology, 9. https://doi.org/10.3389/fcimb.2019.00454
Personalized pharmabiotics and individual nutrition for nosology specific correction of microbiota and local immune system biomarkers / Meleshko T., Rukavchuk R., Drobnych V., & Boyko N. // 10th Anniversary of the European Association for Predictive, Preventive and Personalised (3P) Medicine – EPMA World Congress Supplement 2020. – Pilsen, Czech Republic, 2020. – Р. 125–127.
Personalized Nutrition for Microbiota Correction and Metabolism Restore in Type 2 Diabetes Mellitus Patients. Meleshko T, Rukavchuk R, Levchuk O, Boyko N. Adv Exp Med Biol. 2022;1369:1-16. doi: 10.1007/5584_2021_621. PMID: 33634376.
Personalized pharmabiotics for correction of nosology and individual specific microbiota and immune response. T. V. Meleshko, R. O. Rukavchuk, V. H. Drobnych, N. V. Boyko. EPMA World Congress 2019 : abstracts of the congress (Pilsen, Czech Republic, 19-22 September). Pilsen, 2019.
Antioxidative potential of lactobacilli isolated from the gut of Indian people / Achuthan, A. A., Duary, R. К., Madathil, A., Panwar, Н., Kumar, Н., Batish, V. К., et al., 2012. Molecular Biology Reports 39 (8), 7887–7897. doi: 10.1007/s11033-012-1633-9
Homeostatic Immunity and the Microbiota. Belkaid, Y., Harrison, O. J., 2017. Immunity 46 (4), 562–576. doi: 10.1016/j.immuni.2017.04.008
A potential immunomodulator in COVID-19 infection management. Singh, K., Rao, A., 2021. Probiotics:. Nutrition Research 87,1–12. doi: 10.10l6/j.nutres.2020.12.014
The neuroactive potential o f the human gut microbiota in quality of life and depression. Valles-Colomer, М., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., et al., 2019. Nature microbiology 4 (4), 623–632. doi: 10.1038/s41564-018-0337-x
Патент на корисну модель: Мелешко Т.В., Баті В.В., Паллаг О.В., Симочко Т.М., Бойко Н.В. Патент № 148691 Україна, МПК A61K 36/00, A61K 35/74 (2015.01). Процес одержання композиції пробіотичних штамів та природних пребіотиків для конструювання продуктів харчування, призначених для корекції кишкової мікробіоти. – №u202008154, Заявлено – 21.12.2020. Опубліковано – 08.09.2021, бюл. № 36/2021.
Stress and the Gut-Brain Axis / Kharchenko, Yu. V., Titov H. I., Kryzhanovskyi, D. H., Fedchenko, M. P., Chernenko, H. P., Filipenko, V. V., Miakushko, V. A. (2022). Ukraïnsʹkij Žurnal Medicini, Bìologìï Ta Sportu, 7(4), 137–146. https://doi.org/10.26693/jmbs07.04.137
Сучасні підходи до терапії синдрому подразненого кишечника через призму осі «кишечник – мозок». Sirchak, Ye. S. 2021. Gastroenterology, 52(3), 157–167. https://doi.org/10.22141/2308-2097.52.3.2018.141845
Мікробіом кишечника людини: науково-практичні засади та досягнення. / Іванова А., Яловенко, О., Дуган О. 2021. InterConf, 231–260. https://doi.org/10.51582/interconf.7-8.11.2021.024
Fülling C., Dinan T. G., Cryan J. F. Gut Microbe to Brain Signaling: What Happens in Vagus…. Neuron, 101(6), 2019. 998–1002. https://doi.org/10.1016/j.neuron.2019.02.008
Skolnick S. D., GreigьN. H. Microbes and Monoamines: Potential Neuropsychiatric Consequences of Dysbiosis. Trends in Neurosciences, 42(3), 2019. 151–163. https://doi.org/10.1016/j.tins.2018.12.005
Wall R, Cryan J.F, Ross R.P, Fitzgerald G.F, Dinan TG, Stanton C. Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biol. 2014;817:221–239. PMID: 24997036. doi: 10.1007/978-1-4939-0897-4_10
Olofsson L.E. Bckhed F. The Metabolic Role and Therapeutic Potential of the Microbiome. Endocr. Rev. 2022, 43, 907-926. [Google Scholar] [CrossRef]
Кедик А. В., Куцин О. О. Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу. Clinical Endocrinology and Endocrine Surgery, 4, 2022. 42–58. https://doi.org/10.30978/cees-2022-4-42
Robertson R.C, Manges A.R, Finlay B.B, Prendergast A.J. The human microbiome and child growth – first 1000 days and beyond. Trends Microbiol. 2019;27:131–147. PMID: 30529020. doi: 10.1016/j.tim.2018.09.008
Olin A, Henckel E, Chen Y, Lakshmikanth T, Pou C, Mikes J, et al. Stereotypic immune system development in newborn children. Cell. 2018;174:1277–1292. PMID: 30142345. PMCID: PMC6108833. doi: 10.1016/j. cell.2018.06.045
Jameson KG, Hsiao EY. Linking the gut microbiota to a brain neurotransmitter. Trends Neurosci. 2018;41:413- 414. PMID: 29933773. PMCID: PMC7004240. doi: 10.1016/j.tins.2018.04.001
Крижак Л. М., Калініна Г. П. Метабіотики–розвиток пробіотичної концепції. Технологія виробництва і переробки продукції тваринництва: зб. наук. пр. 2022.№ 1 (170). С. 135–142.
Ефективність застосування екологічно безпечних композицій пробіотиків та наноматеріалів у сільськогосподарському виробництві. Харчишин В. М., Бітюцький В. С., Мельниченко О. М., Цехмістренко О. С., Цехмістренко С. І., Тимошок Н. О., Співак М. Я. Європейський зелений курс та водна політика України в умовах кліматичних змін. Національна науково-практична конференція. (31 березня 2021р. Київ), 51–54. http://rep.btsau.edu.ua/handle/BNAU/6519
Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD / Martyniak, A., Medyńska-Przęczek, A., Wędrychowicz, A., Skoczeń, S., & Tomasik, P. J. 2021. Biomolecules, 11(12), 1903.
Scott E, De Paepe K, Van de Wiele T. Postbiotics and Their Health Modulatory Biomolecules. Biomolecules. 2022 Nov 4;12(11):1640. doi:10.3390/biom12111640.
Algieri F., Tanaskovic N., Rincon C. C., Notario E., Braga D., Pesole G., Rescigno M. Lactobacillus paracasei CNCM I-5220-derived postbiotic protects from the leaky-gut. Frontiers in Microbiology, 14, 2023.724
Żółkiewicz J., Marzec A., Ruszczyński M., Feleszko W. Postbiotics–a step beyond pre-and probiotics. Nutrients, 12(8), 2020. 2189. https://doi.org/10.3390/nu12082189
Śliżewska K., Markowiak-Kopeć P., Śliżewska W. The role of probiotics in cancer prevention. Cancers, 13(1), 2021. 20. https://doi.org/10.3390/cancers13010020
de Almada CN, Almada CN, Martinez RCR, Sant’Ana AS. Paraprobiotics: Evidences on their ability to modify biological responses, inactivation methods and perspectives on their application in foods. Trends Food Sci Technol. 2016;58:96-114. doi:10.1016/j.tifs.2016.09.011.
Manassi C. F., de Souza S. S., Hassemer G. de S., Sartor S., Lima C. M. G., Miotto M., De Dea Lindner J., Rezzadori K., Pimentel T. C., Ramos G. L. de P. A., Esmerino E., Holanda Duarte M. C. K., Marsico E. T., Verruck S. Functional meat products: Trends in pro-, pre-, syn-, para- and post-biotic use. Food Research International, 154, 2022. 111035. https://doi.org/10.1016/j.foodres.2022.111035
Kaźmierczak-Siedlecka K., Skonieczna-Żydecka K., Hupp T., Duchnowska R., Marek-Trzonkowska,N., Połom K. Nextgeneration probiotics – do they open new therapeutic strategies for cancer patients? Gut Microbes, 14(1). 2022. https://doi.org/10.1080/19490976.2022.2035659
Next-Generation Probiotics – The Future of Biotherapeutics. (2022). Microbial Bioactive, 5(1). https://doi.org/10.25163/microbbioacts.514309
Zhang H, Duan Y, Cai F, et al. Next-Generation Probiotics: Microflora Intervention to Human Diseases. Biomed Res Int. 2022 Nov 16;2022:5633403. doi:10.1155/2022/5633403.
Mazier W., Le Corf K., Martinez C., Tudela H., Kissi D., Kropp C., Coubard C., Soto M., Elustondo F., Rawadi G., Claus, S. P. A New Strain of Christensenella minuta as a Potential Biotherapy for Obesity and Associated Metabolic Diseases. Cells, 10(4), 2021. 823. https://doi.org/10.3390/cells10040823
Ndongo S., Khelaifia S., Fournier P.-E., Raoult D. Christensenella massiliensis, a new bacterial species isolated from the human gut. New Microbes and New Infections, 12, 2016. 69–70. https://doi.org/10.1016/j.nmni.2016.04.014
Torres-Sánchez A., Ruiz-Rodríguez A., Ortiz P., Moreno M. A., Ampatzoglou A., Gruszecka-Kosowska A., Monteoliva-Sánchez M., Aguilera M. Exploring Next Generation Probiotics for Metabolic and Microbiota Dysbiosis Linked to Xenobiotic Exposure: Holistic Approach. International Journal of Molecular Sciences, 23(21), 2022. 12917. https://doi.org/10.3390/ijms232112917
Bui T. P. N., de Vos W. M. Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases. Best Practice & Research Clinical Endocrinology & Metabolism, 35(3), 2021. 101504. https://doi.org/10.1016/j.beem.2021.101504
Vallianou N. G., Kounatidis D., Tsilingiris D., Panagopoulos F., Christodoulatos G. S., Evangelopoulos A., Karampela I., Dalamaga, M. The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 24(7), 2023. 6755. https://doi.org/10.3390/ijms24076755
Chang C. J., Lin T. L., Tsai,Y. L., Wu,T. R., Lai W. F., Lu C. C., Lai H. C. Next generation probiotics in disease amelioration. Journal of food and drug analysis, 27(3), 2019. 615–622. https://doi.org/10.1016/j.jfda.2018.12.011
Singh T. P., Natraj B. H. Next-generation probiotics: a promising approach towards designing personalized medicine. Critical Reviews in Microbiology, 47(4), 2021. 479–498. https://doi.org/10.1080/1040841x.2021.1902940
Kaźmierczak-Siedlecka K., Skonieczna-Żydecka K., Hupp T., Duchnowska R., Marek-Trzonkowska N., Połom K. Nextgeneration probiotics–do they open new therapeutic strategies for cancer patients?. Gut Microbes, 14(1), 2022. 2035659. https://doi.org/10.1080/19490976.2022.2035659
Danylenko S., Naumenko O., Potemska O. Biotechnology as the basis of modern innovative food production technologies. Food Resources, 7(12), 2019. 64–73. https://doi.org/10.31073/foodresources2019-12-07
Камінська С. В., Ясінська І. Л., Башта А. О., Основи кріогенних і сушильних технологійлабораторний практикум для здобувачів освіт. ступ. «Бакалавр» спец. 181 «Харчові технології» освіт.-проф. програми «Харчові технології та інженерія» ден. та заоч. форм навч.Нац. ун-т харч. технол. Київ : НУХТ, 2019. 34 с.
Dorofeyev A., Rudenko M., Cheverda Т. STATE OF THE GUT MICROBIOTA IN PATIENTS WITH METABOLICASSOCIATED FATTY LIVER DISEASE WITH TYPE 2 DIABETES MELLITUS. Proceeding of the Shevchenko Scientific Society. Medical Sciences, 2022. 69(2). https://doi.org/10.25040/ntsh2022.02.12
Dorofeyev A. E., Tkach S. M., Prikhodko V. M., Hurkalo Y. Z., Zhihal Y.V., Kryvoruk O. M. Changes in the intestinal microbiome in patients with post––infectious irritable bowel syndrome and current possibilities of their correction. Modern Gastroenterology, 1, 2024. 25–35. https://doi.org/10.30978/mg-2024-1-25
